Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amarin Plans to Seek FDA Approval for CV Indication for Fish Oil Drug

Clinical data for a fish-oil-based drug from Amarin Corporation confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Adults need a regular bedtime, too

Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.

Read More »

AstraZeneca’s Diabetes Drug Farxiga Decreases Risk of Cardiovascular Disease

AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).

Read More »

Amarin’s Fish Oil-Based Drug Dramatically Reduces Cardiovascular Risk

In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.

Read More »

Moderate ‘bad cholesterol’ levels tied to early death for healthy people

Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.

Read More »

Janssen Halts Phase III Kidney Disease Trial Early After Endpoints Were Met

Janssen Pharmaceuticals halted the company’s Phase III chronic kidney disease trial for Invokana early due to the fact that the SGLT2 diabetes drug had already achieved pre-specified efficacy data.

Read More »

Eisai Announces Positive Topline Results from Large-Scale Cardiovascular Outcome Trial for Anti-Obesity Agent Belviq

Eisai Inc. announced positive top-line results from the CAMELLIA-TIMI 61 cardiovascular outcome trial.

Read More »

FDA issues recall on J&J heart device

The U.S. Food and Drug Administration issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve.

Read More »

FDA Approves New Diabetes Drug From Merck, Pfizer

The U.S. FDA approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, which will square off against established drugs in the market.

Read More »

FDA approves NDA for Prexxartan

Carmel Biosciences Inc. received final approval of its New Drug Application from the U.S. Food and Drug Administration for Prexxartan (valsartan) oral solution.

Read More »

Loxo Oncology, Bayer Strike Cancer Deal

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.

Read More »

Novartis’ canakinumab reduced cardiovascular risk by 25 percent in subgroup of CANTOS Phase III trial participants

Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017 and published simultaneously in The Lancet.

Read More »

Stopping aspirin therapy may raise heart attack, stroke risk

Stopping low-dose aspirin therapy without good reason raises the likelihood of heart attack or stroke by nearly 40 percent, a large Swedish study suggests.

Read More »

Aspen to buy remaining AstraZeneca anesthetic rights

AstraZeneca agreed to sell the U.S. rights to a portfolio of anesthetics to South Africa’s Aspen Group.

Read More »

A First: Novartis AG Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too

An anti-inflammatory drug developed for cardiac patients has an exciting, yet unintended side effect – possible prevention of lung cancer.

Read More »

FDA clears Novo Nordisk’s diabetes drug to reduce cardiovascular risk

The FDA approved an expanded use of Novo Nordisk’s diabetes drug Victoza to reduce the risk of cardiovascular events such as heart attack and stroke.

Read More »

Repatha Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).

Read More »

Hundreds of Patient Deaths Linked to Roche’s RA Drug Actemra

Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.

Read More »

SoCal’s Capricor to Reduce Workforce and Shift Focus After Discouraging Trial Results

Shares of Capricor Therapeutics plunged nearly 60 percent in premarket trading after the company announced it was laying off an unknown number of employees following the failure of a mid-stage cardiovascular drug trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom